John O Link
Overview
Explore the profile of John O Link including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng J, Lu B, Carr G, Mwangi J, Wang K, Hao J, et al.
J Pharmacol Exp Ther
. 2024 Aug;
391(1):91-103.
PMID: 39117460
Lenacapavir (LEN), a long-acting injectable, is the first approved human immunodeficiency virus type 1 capsid inhibitor and one of a few Food and Drug Administration-approved drugs that exhibit atropisomerism. LEN...
2.
Kato D, Choy R, Canales E, Dick R, Lake A, Shapiro N, et al.
ACS Med Chem Lett
. 2024 Apr;
15(4):546-554.
PMID: 38628802
Chronic hepatitis B (CHB) virus infection afflicts hundreds of millions of people and causes nearly one million deaths annually. The high levels of circulating viral surface antigen (HBsAg) that characterize...
3.
Link J, Rhee M, Tse W, Zheng J, Somoza J, Rowe W, et al.
Nature
. 2020 Jul;
584(7822):614-618.
PMID: 32612233
Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis. However, some people living with HIV who are heavily...
4.
Yant S, Mulato A, Hansen D, Tse W, Niedziela-Majka A, Zhang J, et al.
Nat Med
. 2019 Sep;
25(9):1377-1384.
PMID: 31501601
People living with HIV (PLWH) have expressed concern about the life-long burden and stigma associated with taking pills daily and can experience medication fatigue that might lead to suboptimal treatment...
5.
Link J, Taylor J, Trejo-Martin A, Kato D, Katana A, Krygowski E, et al.
Bioorg Med Chem Lett
. 2019 Jun;
29(16):2415-2427.
PMID: 31230974
Direct-acting antiviral inhibitors have revolutionized the treatment of hepatitis C virus (HCV) infected patients. Herein is described the discovery of velpatasvir (VEL, GS-5816), a potent pan-genotypic HCV NS5A inhibitor that...
6.
Taylor J, Zipfel S, Ramey K, Vivian R, Schrier A, Karki K, et al.
Bioorg Med Chem Lett
. 2019 May;
29(16):2428-2436.
PMID: 31133531
Treatment of hepatitis C virus (HCV) infection has been historically challenging due the high viral genetic complexity wherein there are eight distinct genotypes and at least 86 viral subtypes. While...
7.
Link J, Taylor J, Xu L, Mitchell M, Guo H, Liu H, et al.
J Med Chem
. 2016 Aug;
59(16):7696.
PMID: 27529494
No abstract available.
8.
Lawitz E, Dvory-Sobol H, Doehle B, Worth A, McNally J, Brainard D, et al.
Antimicrob Agents Chemother
. 2016 Jun;
60(9):5368-78.
PMID: 27353271
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. In a phase 1b...
9.
Cheng G, Tian Y, Doehle B, Peng B, Corsa A, Lee Y, et al.
Antimicrob Agents Chemother
. 2016 Jan;
60(3):1847-1853.
PMID: 26824950
Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat chronic hepatitis C virus (HCV) infection. Here, we report key preclinical...
10.
Kwon H, Xing W, Chan K, Niedziela-Majka A, Brendza K, Kirschberg T, et al.
PLoS One
. 2015 Apr;
10(4):e0122844.
PMID: 25856426
Ledipasvir, a direct acting antiviral agent (DAA) targeting the Hepatitis C Virus NS5A protein, exhibits picomolar activity in replicon cells. While its mechanism of action is unclear, mutations that confer...